{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/aphthous-ulcer/management/management/","result":{"pageContext":{"chapter":{"id":"99359365-5779-5dc9-a70c-06c437fa4bec","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 9d369c04-f02d-4503-a9ef-5efbf147ebf7 --><h2>Scenario: Management of aphthous ulcer</h2><!-- end field 9d369c04-f02d-4503-a9ef-5efbf147ebf7 -->","summary":"Covers the assessment and management of aphthous ulcers, and when to refer someone with oral ulceration.","htmlStringContent":"<!-- begin item d0c4a446-bd11-44d5-9e2c-8b9348a386fc --><!-- begin field 08ee952e-ab38-49bc-9903-acbc0157ab2c --><p>From age 5 years onwards.</p><!-- end field 08ee952e-ab38-49bc-9903-acbc0157ab2c --><!-- end item d0c4a446-bd11-44d5-9e2c-8b9348a386fc -->","topic":{"id":"0d0cd284-920f-5a4d-af22-e60387034bd3","topicId":"a8bbf75a-0ba0-4cf4-aa6d-c04c197470ee","topicName":"Aphthous ulcer","slug":"aphthous-ulcer","lastRevised":"Last revised in April 2017","chapters":[{"id":"c5681466-1d53-592e-a6f3-ef09c26590f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57a52c12-af9a-58cc-8652-e510af025137","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"78568ea4-ac58-5f85-b614-4f6349e25cc6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4cc5e97a-0fae-51bc-808e-e6d06f3d1bf0","slug":"changes","fullItemName":"Changes"},{"id":"133d9798-49cd-5211-bf2a-bac0f674f0a1","slug":"update","fullItemName":"Update"}]},{"id":"c8dc5503-619d-58f3-86ff-d0321f0ceabb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"53b4a0fd-899b-547c-8522-7ca2034e0739","slug":"goals","fullItemName":"Goals"},{"id":"a531a007-31cf-5b5c-9120-0c2e4d33757d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ec63555-d923-5190-a236-662ab9fd12e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f3d6c286-8aac-5529-87e8-073f78d63ccb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"edb5e193-54cf-5552-83b9-38aa7f31e0b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ec0b271-e6c7-58fe-8588-6fede72a6528","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"acbcb9eb-b6e3-5544-a64c-bbf327bf7196","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e8fbc455-fba9-5a7b-8488-ab5ba5cb7f23","slug":"definition","fullItemName":"Definition"},{"id":"5d4f91c1-0b7e-5b2e-a7d9-3cb851a4724f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8f142ca7-f145-5707-96bd-2e872abec04c","slug":"causes","fullItemName":"Causes"},{"id":"0fe4abe0-ac8a-596c-89fb-6308469ffccc","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"6b590897-ea1c-5f81-a10f-5231856a4218","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"85e6ad3b-53b9-569a-85d9-0d89cade7baf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"9e8b8716-00db-5198-848b-1499dbe6ebfc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c2255f6f-94df-5102-b8f5-b0ce847ccd0b","fullItemName":"Management","slug":"management","subChapters":[{"id":"99359365-5779-5dc9-a70c-06c437fa4bec","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"043b58c8-35cb-5bde-947d-ad6745ce6442","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fdc1200c-28a7-549e-badb-49b57809d89d","slug":"beclometasone-dipropionate","fullItemName":"Beclometasone dipropionate"},{"id":"8a9bea80-2abd-5c4c-8f3f-1808d885ad28","slug":"betamethasone-soluble-tablets","fullItemName":"Betamethasone soluble tablets"},{"id":"6b4324bf-8c13-548c-aa78-c03fe2d7ae38","slug":"hydocortisone-oromucosal-tablets","fullItemName":"Hydocortisone oromucosal tablets"},{"id":"4a2cbdae-edfd-5ee4-a8c6-fb2bc2ee37d6","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"},{"id":"71959a98-dede-5b80-8412-62b92c7172f4","slug":"benzydamine-hydrochloride","fullItemName":"Benzydamine hydrochloride"},{"id":"0973c3a1-9b56-5a4e-8be8-2bdc1a2086e3","slug":"chlorhexidine","fullItemName":"Chlorhexidine"},{"id":"d2706d4a-55cb-558d-b051-48b760c89259","slug":"doxycycline-rinses","fullItemName":"Doxycycline rinses"},{"id":"4113f257-00a4-5ae5-bf7e-6779f04fc835","slug":"lidocaine-hydrochloride","fullItemName":"Lidocaine hydrochloride"},{"id":"1856d033-bfca-5001-b8ed-bb55f0981a0e","slug":"cyanocobalamin","fullItemName":"Cyanocobalamin"}]},{"id":"3941ff63-446e-556a-87b3-af80dbd8dba9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"94c5ca61-9355-514f-ba99-256e7c8d2913","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a71bf9fe-164d-54fb-82e2-2aa5ceec590b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a24bf4ae-506c-51aa-84b7-73436ec0ac43","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7f107881-b247-54f5-850f-c340b8187b07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"41016397-9e4e-5617-9713-825e45d3ae1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e858140-2320-5176-9cd5-22bec3ae597a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fb71f4be-d743-5e4f-81a8-da0a88971d9f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c2255f6f-94df-5102-b8f5-b0ce847ccd0b","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0d59de82-7118-502a-8359-01960adfeae6","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field eb1a0ffa-cfc8-4719-af2d-310ca73c794a --><h3>How should I manage a person with aphthous ulcer?</h3><!-- end field eb1a0ffa-cfc8-4719-af2d-310ca73c794a -->","summary":null,"htmlStringContent":"<!-- begin item 011376d5-4555-45ed-ad4d-cbe67908fa54 --><!-- begin field fa214244-66af-43d3-bfeb-3b7033c33631 --><ul><li><strong><strong>If <a class=\"topic-reference internal-reference\" href=\"/topics/aphthous-ulcer/diagnosis/differential-diagnosis/\">symptoms and signs</a> and/or the results of <a class=\"topic-reference internal-reference\" href=\"/topics/aphthous-ulcer/diagnosis/\">preliminary tests</a> suggest an underlying cause for oral ulceration, refer for specialist assessment, with urgency determined using clinical judgement, or treat the identified condition in primary care where appropriate.</strong></strong></li><li><strong>If aphthous ulcer is suspected:</strong><ul><li><strong>Advise the person about avoiding 'trigger factors' including oral trauma and certain foods and drinks </strong>(such as coffee, chocolate, peanuts, and gluten-containing products).<ul><li>For all people with local trauma (e.g. from sharp and/or broken teeth, dentures and orthodontic appliances, and biting during chewing) appropriate dental treatment should be advised.</li></ul></li><li><strong>Offer the person information on the natural history of aphthous ulcer.</strong> Patient information leaflets are available from the <a href=\"http://www.bsom.org.uk/wp-content/uploads/pdf/PIL2016/BSOM-PiL-Recurrent-Aphthous-Stomatitis-April-2016.pdf\" data-hyperlink-id=\"66b25ce1-1709-48e3-bbc1-a98d003d45d7\">British Society for Oral Medicine</a> and <a href=\"https://patient.info/health/mouth-ulcers-leaflet\" data-hyperlink-id=\"d44b8d70-8629-4a48-b33d-a98d003d45fe\">Patent.info</a>.</li><li><strong>Depending on the severity of the person's symptoms, consider offering medication to achieve pain relief, reduction of ulcer duration, and reduction in frequency of episodes. </strong><ul><li>If ulcers are infrequent, mild, and not interfering with daily activities (for example eating), treatment may not be needed.</li><li>First-line treatment is usually a topical corticosteroid such as hydrocortisone oro-mucosal tablets, beclomethasone spray (delivered via an inhaler device — off-license use), or betamethasone soluble tablets. Duration of treatment is decided on a case-by-case basis.</li><li>Other therapies that can be used either alone or in addition include topical anaesthetics such as lidocaine, topical analgesic/anti-inflammatory agents such as benzydamine, and topical antimicrobial agents such as chlorhexidine gluconate oral solution, or doxycycline rinses.</li><li>For people with severe recurrent aphthous ulceration, a short course of systemic prednisolone can be prescribed.</li><li>Consider prescribing or advising the use of an oral vitamin B12 (cyanocobalamin) supplement, irrespective of serum vitamin B12 levels.</li><li>For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/aphthous-ulcer/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Consider specialist referral if ulceration is severe and does not respond to </strong><strong>topical treatments or systemic corticosteroids.</strong></li></ul></li></ul><!-- end field fa214244-66af-43d3-bfeb-3b7033c33631 --><!-- end item 011376d5-4555-45ed-ad4d-cbe67908fa54 -->","subChapters":[{"id":"669e58ec-c8aa-5d3f-952c-4e1f66819ec8","slug":"basis-for-recommendation-6d4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8272b409-0ba5-4491-acbe-59c19b8c6a3a --><h4>Basis for recommendation</h4><!-- end field 8272b409-0ba5-4491-acbe-59c19b8c6a3a -->","summary":null,"htmlStringContent":"<!-- begin item 6d408603-85f6-427a-b230-ecc0a1569b9f --><!-- begin field 6eb9153f-928e-4faf-843d-0a7faf4d568b --><p>The recommendations on management of a person with aphthous ulcer are largely based on expert opinion in two narrative review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">Staines and Greenwood, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">Scully, 2016</a>].</p><h5>Referral or treatment of people with underlying conditions</h5><p>The recommendation to refer people with suspected underlying conditions with urgency determined by clinical judgement, or to treat in primary care if appropriate, is pragmatic, based on what CKS considers to be good medical practice.</p><h5>Recommended treatments</h5><p>The information on the specific preparations of topical corticosrteroids, and anti-inflammatory and anti-bacterial solutions recommended for the treatment of aphthous ulcer is from the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">BNF 73, 2017</a>].</p><h5>Vitamin B12 prescription</h5><p>The recommendation to consider prescribing vitamin B12 even where serum levels (if measured) are within the normal range is based on information from studies which have demonstrated evidence of benefit from vitamin B12 in the absence of deficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">Scully, 2016</a>].</p><h5>Specialist referral if ulceration is severe and does not respond to topical treatments or systemic corticosteroids.</h5><p>This recommendation is based on information that thalidomide may be an appropriate treatment for people with severe aphthous ulceration who have not responded to other therapies, and specialist supervision would therefore be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">Scully, 2016</a>].</p><!-- end field 6eb9153f-928e-4faf-843d-0a7faf4d568b --><!-- end item 6d408603-85f6-427a-b230-ecc0a1569b9f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}